Key Takeaways
- Boston Scientific shares fell to a 52-week low of $60.54, representing a 36% decline for the year
- Stifel reduced its price target to $85 from $90 based on electrophysiology purchasing data before Q1 2026 results
- First-quarter 2026 financial results scheduled for release on April 22, 2026
- Several Wall Street firms continue recommending the stock with Buy/Outperform ratings — RBC maintains $115 target, UBS at $105
- InvestingPro identifies BSX as significantly undervalued with a Fair Value estimate of $76.66
Shares of Boston Scientific have experienced significant turbulence throughout 2026. The medical device manufacturer saw its stock price sink to a 52-week low of $60.54 on April 21, with current trading hovering between $60.43 and $60.99 — dramatically lower than its 52-week peak of $109.50.
Boston Scientific Corporation, BSX
The steep 36% year-to-date decline has wiped out substantial value from the company’s $90.6 billion market capitalization.
Ahead of the company’s first-quarter 2026 financial report, Stifel analyst Rick Wise revised his price target on BSX downward to $85 from a previous $90. However, Wise maintained his Buy recommendation on the medical technology stock.
The target adjustment stems from Stifel’s proprietary monthly electrophysiology (EP) hospital-purchasing database, which provides early indicators of quarterly performance ahead of official earnings announcements.
The firm’s data showed January reporting at approximately 92% complete, February at roughly 85%, and March tracking at about 60% — offering a substantive but incomplete view of EP revenue performance.
According to Stifel’s analysis, the Q1 US EP consensus revenue estimate of approximately $587 million appears “within the band of achievability” for BSX. While not an enthusiastic projection, it suggests expectations are reasonably aligned with reality.
Stifel’s methodology involves benchmarking against Johnson & Johnson and Abbott Laboratories using the same EP purchasing information to validate projected versus reported revenues. The investment firm successfully identified potential downside risks to US EP consensus figures in the previous quarter using this approach.
Wall Street Maintains Optimism Despite Price Reductions
Despite the pronounced selloff, most analysts covering Boston Scientific remain constructive. Truist Securities maintained its Buy recommendation while trimming its target to $90 from $92. The firm anticipates cardiovascular segment growth of 8.5% to 9% in the forthcoming quarterly report.
RBC Capital reaffirmed its Outperform rating with a $115 price objective following direct discussions with Boston Scientific management regarding future growth opportunities.
UBS preserved its Buy rating and $105 target in response to positive CHAMPION-AF trial data for the Watchman heart implant device. The clinical trial successfully achieved all primary and secondary endpoints — a favorable result that UBS believes mitigates headline risk.
However, complications emerged from the data. The Watchman device demonstrated a marginally elevated ischemic stroke rate when compared to non-vitamin K antagonist oral anticoagulants (NOACs), disappointing certain market participants.
Piper Sandler maintained its Overweight stance following consultation with a high-volume electrophysiologist who anticipates increased Watchman adoption despite the stroke-related findings.
Valuation Metrics Suggest Opportunity
InvestingPro has identified BSX among its most undervalued equities, establishing a Fair Value benchmark of $76.66 — approximately 27% higher than current market prices.
Top-line performance remains robust, with Boston Scientific delivering nearly 20% revenue growth over the trailing twelve months. Fundamentally, the business continues executing well — the stock price simply hasn’t reflected that reality.
Market attention now shifts to April 22, when BSX releases Q1 2026 financial results. That earnings announcement will provide the first concrete evidence of whether EP revenues performed as Stifel’s purchasing data indicates they should.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
